[go: up one dir, main page]

WO2008101029A3 - Use of thiazole, oxazole and imidazole compounds for the treatment of sodium channel-mediated diseases or conditions - Google Patents

Use of thiazole, oxazole and imidazole compounds for the treatment of sodium channel-mediated diseases or conditions Download PDF

Info

Publication number
WO2008101029A3
WO2008101029A3 PCT/US2008/053879 US2008053879W WO2008101029A3 WO 2008101029 A3 WO2008101029 A3 WO 2008101029A3 US 2008053879 W US2008053879 W US 2008053879W WO 2008101029 A3 WO2008101029 A3 WO 2008101029A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxazole
thiazole
treatment
conditions
sodium channel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/053879
Other languages
French (fr)
Other versions
WO2008101029A2 (en
Inventor
Sultan Chowdhury
Robert Fraser
Jianmin Fu
Rajender Kamboj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenon Pharmaceuticals Inc
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of WO2008101029A2 publication Critical patent/WO2008101029A2/en
Publication of WO2008101029A3 publication Critical patent/WO2008101029A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention is directed to methods of using thiazole, oxazole and imidazole compounds of formula (I): wherein A is -S-, -O- or N(R5), and R1, R2, R3 and R5 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
PCT/US2008/053879 2007-02-13 2008-02-13 Use of thiazole, oxazole and imidazole compounds for the treatment of sodium channel-mediated diseases or conditions Ceased WO2008101029A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88972107P 2007-02-13 2007-02-13
US60/889,721 2007-02-13
US88987207P 2007-02-14 2007-02-14
US60/889,872 2007-02-14

Publications (2)

Publication Number Publication Date
WO2008101029A2 WO2008101029A2 (en) 2008-08-21
WO2008101029A3 true WO2008101029A3 (en) 2009-02-19

Family

ID=39427636

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/053879 Ceased WO2008101029A2 (en) 2007-02-13 2008-02-13 Use of thiazole, oxazole and imidazole compounds for the treatment of sodium channel-mediated diseases or conditions

Country Status (1)

Country Link
WO (1) WO2008101029A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905525D0 (en) * 2009-03-31 2009-05-13 Univ Leiden Compounds and uses
US8975411B2 (en) 2010-07-28 2015-03-10 Neugen Pharma Inc. Therapeutic agent for neurological diseases
CN102336720B (en) * 2011-03-02 2016-01-13 华中科技大学 Thiazolamine derivative and preparation method and application
EP2832731A4 (en) 2012-03-27 2015-08-19 Shionogi & Co Aromatic heterocyclic five-membered ring derivative having trpv4 inhibitory activity
AU2021385572A1 (en) 2020-11-25 2023-06-22 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1205478A1 (en) * 1999-08-06 2002-05-15 Takeda Chemical Industries, Ltd. p38MAP KINASE INHIBITORS
WO2004094395A2 (en) * 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2006124744A1 (en) * 2005-05-16 2006-11-23 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
WO2007109324A2 (en) * 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1205478A1 (en) * 1999-08-06 2002-05-15 Takeda Chemical Industries, Ltd. p38MAP KINASE INHIBITORS
WO2004094395A2 (en) * 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2006124744A1 (en) * 2005-05-16 2006-11-23 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
WO2007109324A2 (en) * 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ATTIMARAD M, SOMASEKHAR V, MOHAN S: "Synthesis of 2-N-Acylamino-4-Arylthiazole-5-Acetic acid/esters for their anti-inflammatory and analgesic activities", ASIAN JOURNAL OF CHEMISTRY, vol. 16, no. 1, 2004, pages 179 - 182, XP009100703 *
BHARGAVA P N, LAKHAN R, TRIPATHI R: "Local Anaesthetics. Part II: Synthesis of 2-(N,N-disubstituted aminoacetamido)-4-p-fluorophenyl and m-methoxyphenyl thiazoles", JOURNAL OF INDIAN CHEMICAL SOCIETY, vol. LIX, June 1982 (1982-06-01), pages 773 - 775, XP009100709 *
BHATTACHARYA P, LEONARD J T, ROY K: "Exploring QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists using FA and GFA techniques", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 13, 2005, pages 1159 - 1165, XP002482381 *
PRIEST B T ET AL., BIOCHEMISTRY, vol. 43, 2004, pages 9866 - 9876, XP002482380 *

Also Published As

Publication number Publication date
WO2008101029A2 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
MX2009008338A (en) Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions.
WO2008046087A3 (en) Spiro compounds and their uses as therapeutic agents
MX2009003874A (en) Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents.
WO2008094909A3 (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
WO2010045251A3 (en) Spiro-oxindole compounds and their use as therapeutic agents
TNSN07384A1 (en) Spiroheterocyclic compounds and their uses as therapeutic agents
WO2008147864A3 (en) Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
WO2006110917A3 (en) Spiro-oxindole compounds and their uses as therapeutic agents
WO2008115999A8 (en) Biaryl and biheteroaryl compounds useful in treating iron disorders
WO2008046084A3 (en) Spiroheterocyclic compounds and their uses as therapeutic agents
MX2009012168A (en) Pyrrolopyridine derivatives and their use as bace inhibitors.
PH12015502323A1 (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
NZ593440A (en) Aminopyrazole compounds useful for inhibiting chk1
NZ622072A (en) Synthetic methods for spiro-oxindole compounds
MA38323B1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
MX2010008460A (en) Thiazole derivative and use thereof as vap-1 inhibitor.
WO2008109856A3 (en) Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions
WO2008151288A3 (en) Aromatic and heteroaromatic compounds useful in treating iron disorders
WO2009121939A3 (en) C-aryl glycoside compounds for the treatment of diabetes and obesity
MX341341B (en) Benzamide derivatives and their use as hsp90 inhibtors.
WO2010132352A3 (en) Spiro compounds and their use as therapeutic agents
WO2008101029A3 (en) Use of thiazole, oxazole and imidazole compounds for the treatment of sodium channel-mediated diseases or conditions
MX2009009466A (en) Tricyclic compounds useful in treating iron disorders.
DE602007001463D1 (en) PYRIMIDINE, CHINAZOLIN, PTERIDINE AND TRIAZINE DERIVATIVES
MX2008016358A (en) Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08729788

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08729788

Country of ref document: EP

Kind code of ref document: A2